Suggested remit: To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for treating non-small-cell lung cancer after platinum-based chemotherapy.
Status In progress
Process STA 2018
ID number 1146

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
25 April 2018 - 24 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
13 February 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance